Key Stats for UnitedHealth Stock
- 52-Week Range: $234.60 to $404.15
- Current Price: $384.98
- Street Mean Target: ~$390
- TIKR Target Price (Mid): ~$652
- TIKR Annualized IRR (Mid): ~12% per year
- Q1 2026 Revenue: $109.6B (up ~9% YoY)
- Q1 2026 Medical Cost Ratio: 87.5%
- Q1 2026 Adjusted EPS: $7.20
- Dividend Yield: 2.3%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Two Things Are True at the Same Time
UnitedHealth Group (UNH) is the largest health insurer in the United States, covering roughly 50 million people through UnitedHealthcare while simultaneously running Optum, one of the largest healthcare services businesses in the world, with over 90,000 physicians and the country’s largest pharmacy benefit manager.
The company had one of the worst operating years in its recent history in 2025. Elevated Medicare Advantage medical costs, the aftermath of the Change Healthcare cyberattack, and losses from Optum Health’s value-based care arrangements all hit simultaneously. The stock fell from above $600 in late 2024 to a low of $234 in March 2026, then bounced sharply to $404 in April.
It has since pulled back to $385, the bounce was real. But the stock is not back where it was, and the reason is straightforward: UnitedHealth confirmed it is facing both criminal and civil investigations from the Department of Justice related to its Medicare billing practices, and that investigation has no visible resolution timeline.
See historical and forward estimates for UnitedHealth stock (It’s free!) >>>
What the EPS Chart Tells Us About the Cycle
EPS compounded steadily from $19.02 in 2021 to a peak of $27.66 in 2024, one of the most consistent earnings growth records in large-cap healthcare. Then in 2025, it fell sharply to $16.35, a 41% decline in a single year.
The two causes are distinct. Optum Health incurred a massive operating loss as the company unwound value-based care contracts in which it had been absorbing medical costs without adequate rate coverage. UnitedHealthcare’s medical cost ratio was 87.5%, well above the 83-84% range the business needs to achieve its target margins.
Consensus expects EPS to recover from around $18 in 2026 to around $21 in 2027 and then to around $24 in 2028 as Optum losses normalize and the MCR retreats. Getting back to the 2024 peak is a late-decade story, not a near-term one.
Why the Free Cash Flow Chart Still Makes the Case
Even through all of this, UnitedHealth generated $16.08 billion in free cash flow in 2025. That number deserves emphasis. A business absorbing a major operating loss in one segment, facing a criminal investigation, withdrawing its annual guidance, and still producing $16 billion in cash is telling you something important about the durability of the underlying franchise.
FCF peaked at $25.68 billion in 2023 and has declined alongside the earnings pressure. But it has not gone negative, the dividend has been maintained, and the company has continued buying back shares. When the Optum losses clear and the MCR normalizes, FCF recovers toward $20 billion or higher. That is the number underpinning the long-term valuation thesis.
See how UnitedHealth performs against its peers in TIKR (It’s free!) >>>
What the TIKR Model Implies at the Current Price
The TIKR model targets around $652 per share in the mid case over about 4.6 years, implying roughly 70% total return at around 12% annually. Revenue growth of around 6% per year, net income margins of around 5%, and EPS growth of around 11% are the inputs.
The Street target of around $390 implies little to no upside from the current price, which is a meaningful divergence from the TIKR model. That gap reflects exactly how much uncertainty analysts are embedding around the investigation. The 8-year mid case extends to around $930. The range of outcomes is wide in a way that few other stocks in this series can match.
What Could Drive the Returns Higher or Lower
The bull case is that the headwinds are temporary and defined. Optum Health is actively contracting out of its value-based care arrangements, meaning loss-generating contracts are being exited systematically. Management has guided that Medicare Advantage margins will recover to their long-term 3-5% target range. CEO Stephen Hemsley, who built UNH into what it is over decades, came back specifically to manage this reset.
The bear case is the investigation, and it cannot be minimized. The probes focus on whether UnitedHealth inflated diagnoses to trigger higher government payments, with allegations that diagnoses were added without physician confirmation. DOJ attorneys interviewed multiple former UnitedHealth clinicians about whether they felt pressured to add diagnoses without supporting evidence.
The potential penalties range from meaningful to severe, depending on what the government finds and pursues. Every other number in this piece is conditioned on that process resolving without fundamental damage to the business.
Is UNH Worth Buying at $385?
This is genuinely harder than most of the stocks in this series, and anyone who tells you otherwise is not taking the investigation seriously enough.
The franchise is real. The FCF is real. The EPS recovery trajectory, if it plays out, produces a stock worth substantially more than $385. The TIKR mid-case of around $652 at roughly 12% annually, plus a 2.3% dividend, is a return profile hard to find in large-cap healthcare.
What is also real is that a criminal and civil investigation into the largest Medicare Advantage payer in the country is not a standard operating headwind. For investors with a long time horizon and a genuine tolerance for that kind of uncertainty, the current price offers a wide gap between where the stock sits and where the model says it could go.
For investors who need more clarity on the downside before committing, UNH may require patience; the next earnings print alone cannot provide.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
